A phase II, randomized, open-label study to assess the efficacy of extended-dose schedule administration of darbepoetin alfa in cancer patients with chemotherapy-induced anemia

Lee Schwartzberg; Timothy Rearden; Lorrin Yee; Barry Mirtsching; Veena Charu; Hung Lam; Tom Lillie; Ronald Burkes; Peter Silberstein

A phase II, randomized, open-label study to assess the efficacy of extended-dose schedule administration of darbepoetin alfa in cancer patients with chemotherapy-induced anemia

Lee Schwartzberg, Timothy Rearden, Lorrin Yee, Barry Mirtsching, Veena Charu, Hung Lam, Tom Lillie, Ronald Burkes, Peter Silberstein

Department of Medicine

Research output: Contribution to journal › Article

1 Scopus citations

Original language	English
Pages (from-to)	22-23
Number of pages	2
Journal	Journal of Supportive Oncology
Volume	5
Issue number	4 SUPPL. 2
Publication status	Published - Apr 2007

All Science Journal Classification (ASJC) codes

Cancer Research
Oncology

Cite this

Schwartzberg, L., Rearden, T., Yee, L., Mirtsching, B., Charu, V., Lam, H., ... Silberstein, P. (2007). A phase II, randomized, open-label study to assess the efficacy of extended-dose schedule administration of darbepoetin alfa in cancer patients with chemotherapy-induced anemia. Journal of Supportive Oncology, 5(4 SUPPL. 2), 22-23.

A phase II, randomized, open-label study to assess the efficacy of extended-dose schedule administration of darbepoetin alfa in cancer patients with chemotherapy-induced anemia. / Schwartzberg, Lee; Rearden, Timothy; Yee, Lorrin; Mirtsching, Barry; Charu, Veena; Lam, Hung; Lillie, Tom; Burkes, Ronald; Silberstein, Peter.

In: Journal of Supportive Oncology, Vol. 5, No. 4 SUPPL. 2, 04.2007, p. 22-23.

Research output: Contribution to journal › Article

Schwartzberg, Lee ; Rearden, Timothy ; Yee, Lorrin ; Mirtsching, Barry ; Charu, Veena ; Lam, Hung ; Lillie, Tom ; Burkes, Ronald ; Silberstein, Peter. / A phase II, randomized, open-label study to assess the efficacy of extended-dose schedule administration of darbepoetin alfa in cancer patients with chemotherapy-induced anemia. In: Journal of Supportive Oncology. 2007 ; Vol. 5, No. 4 SUPPL. 2. pp. 22-23.

@article{0e645455cbb641fca12309c544def909,

title = "A phase II, randomized, open-label study to assess the efficacy of extended-dose schedule administration of darbepoetin alfa in cancer patients with chemotherapy-induced anemia",

author = "Lee Schwartzberg and Timothy Rearden and Lorrin Yee and Barry Mirtsching and Veena Charu and Hung Lam and Tom Lillie and Ronald Burkes and Peter Silberstein",

year = "2007",

month = "4",

language = "English",

volume = "5",

pages = "22--23",

journal = "Journal of Supportive Oncology",

issn = "1544-6794",

publisher = "Biolink Communications, Inc.",

number = "4 SUPPL. 2",

}

TY - JOUR

T1 - A phase II, randomized, open-label study to assess the efficacy of extended-dose schedule administration of darbepoetin alfa in cancer patients with chemotherapy-induced anemia

AU - Schwartzberg, Lee

AU - Rearden, Timothy

AU - Yee, Lorrin

AU - Mirtsching, Barry

AU - Charu, Veena

AU - Lam, Hung

AU - Lillie, Tom

AU - Burkes, Ronald

AU - Silberstein, Peter

PY - 2007/4

Y1 - 2007/4

UR - http://www.scopus.com/inward/record.url?scp=34250615108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250615108&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:34250615108

VL - 5

SP - 22

EP - 23

JO - Journal of Supportive Oncology

JF - Journal of Supportive Oncology

SN - 1544-6794

IS - 4 SUPPL. 2

ER -

A phase II, randomized, open-label study to assess the efficacy of extended-dose schedule administration of darbepoetin alfa in cancer patients with chemotherapy-induced anemia

All Science Journal Classification (ASJC) codes

Cite this

Access to Document